placebo in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results NIH NIAID ACTT-1, 2020 (REV) 1.37 [0.97; 1.93]
1.37 [0.97 ; 1.93 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable deathsdetailed results CAP-China (Wang et al.), 2020 (REV) 0.91 [0.41; 2.03]
NIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76]
1.40 [0.73 ; 2.71 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 56% 1,298 moderate not evaluable deaths (time to event analysis only)detailed results NIH NIAID ACTT-1, 2020 (REV) 1.82 [1.20; 2.76]
1.82 [1.20 ; 2.76 ] NIH NIAID ACTT-1, 2020 (REV) 1 0% 1,062 NA not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 (REV) 1.05 [0.61; 1.82]
1.05 [0.61 ; 1.82 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 (REV) 0.81 [0.57; 1.15]
NIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89]
0.78 [0.68 ; 0.89 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,299 moderate not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 (REV) 0.83 [0.44; 1.56]
0.83 [0.44 ; 1.56 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 (REV) 0.73 [0.42; 1.27]
NIH NIAID ACTT-1, 2020 (REV) 0.74 [0.57; 0.97]
0.74 [0.58 ; 0.94 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,298 moderate not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 (REV) 1.01 [0.18; 5.66]
1.01 [0.18 ; 5.66 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 236 NA not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 (REV) 0.81 [0.57; 1.15]
NIH NIAID ACTT-1, 2020 (REV) 0.78 [0.67; 0.89]
0.78 [0.68 ; 0.89 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,299 moderate not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 (REV) 0.41 [0.13; 1.26]
0.41 [0.13 ; 1.26 ] CAP-China (Wang et al.), 2020 (REV) 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 (REV) 1.56 [0.81; 3.00]
NIH NIAID ACTT-1, 2020 (REV) 1.39 [1.04; 1.84]
1.41 [1.09 ; 1.83 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,296 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 (REV) 2.00 [0.12; 32.41]
NIH NIAID ACTT-1, 2020 (REV) 1.56 [0.55; 4.43]
1.61 [0.61 ; 4.27 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,296 moderate not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 (REV) 2.76 [0.99; 7.71]
NIH NIAID ACTT-1, 2020 (REV) 1.49 [0.85; 2.61]
1.73 [1.03 ; 2.91 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 6% 1,296 moderate not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 (REV) 0.92 [0.36; 2.36]
NIH NIAID ACTT-1, 2020 (REV) 1.19 [0.43; 3.30]
1.03 [0.52 ; 2.07 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,296 low not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 (REV) 2.00 [0.12; 32.41]
NIH NIAID ACTT-1, 2020 (REV) 1.04 [0.21; 5.16]
1.22 [0.30 ; 4.91 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,296 moderate not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 (REV) 0.99 [0.03; 29.94]
NIH NIAID ACTT-1, 2020 (REV) 0.98 [0.62; 1.56]
0.98 [0.62 ; 1.55 ] CAP-China (Wang et al.), 2020 (REV), NIH NIAID ACTT-1, 2020 (REV) 2 0% 1,296 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-19 17:56 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 650
- roots T: 650
